Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Loss of surface CD19 expression by leukemic cells leads to resistance and relapse to CD19-targeted CAR-T therapies. Here the authors show that loss of SPPL3 in malignant B cells results in hyperglycosylation of CD19.
Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , , |
---|---|
Μορφή: | Άρθρο |
Γλώσσα: | English |
Έκδοση: |
Nature Portfolio
2022-06-01
|
Σειρά: | Nature Communications |
Διαθέσιμο Online: | https://doi.org/10.1038/s41467-022-31035-7 |